Table 3.

Survival analyses^a

Variables	Univariate analysis				Multivariate analysis
	n	Median survival (mo)	95% CI	p-value	n	HR	95% CI	p-value
Age (n = 662)
15–39 years	70	36.8	27.0–46.6	0.002	52	1.57	0.98–2.53	0.060
40–49 years	152	41.2	32.4–49.9		123	1.34	0.97–1.86	0.077
≥50 years	440	46.2	42.2–50.2		293	Ref.
Site (n = 656)
Right-sided	242	35.7	30.6–40.8	<0.001	163	1.28	0.94–1.74	0.12
Left-sided	414	48.8	44.9–52.7		305	Ref.
Differentiated (n = 656)
Well-moderately	450	48.5	44.5–52.4	<0.001	331	Ref.
Poorly	206	31.6	25.0–38.1		137	1.35	0.96–1.90	0.088
KRAS (n = 661)
Wild-type	358	48.2	43.1–53.4	0.013	259	Ref.
Mutant	303	40.7	35.1–46.4		209	1.51	1.17–1.95	0.002
BRAF (n = 662)
Wild-type	602	45.7	42.1–49.3	<0.001	425	Ref.
Mutant	60	35.9	15.8–56.0		43	1.86	1.20–2.89	0.005
PIK3CA (n = 658)
Wild-type	560	45.6	41.6–49.6	0.111
Mutant	98	42.4	33.6–51.1
MMR status (n = 498)
Proficient	470	44.8	40.3–49.4	0.016	442	Ref.	1.20–3.90	0.010
Deficient	28	35.9	8.5–63.4		26	2.17
Histology (n = 633)
AC	572	47.2	43.6–50.9	<0.001	416	Ref.
AC with SC	26	19.3	10.7–27.8		19	2.63	1.30–5.33	0.007
SRCC	35	16.4	11.3–21.5		33	3.11	1.73–5.60	<0.001

The Bold values are statistically significant

A p-value < 0.05 indicates statistical significance

CI confidence interval, HR hazard ratio, Ref. reference, SRCC signet ring cell colorectal cancer, AC with SC adenocarcinoma with signet ring cell component, AC adenocarcinoma

^aOnly conducted among patients with available data